Cystatin B Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
{{infobox .infobox-protein
| protein = Cystatin B
| gene = CSTB
| uniprot = P04080
| pdb = 1QXM, 2NBD
| mw = 11.1 kDa
| location = Cytoplasm, nucleus
| family = Cystatin family (stefin)
}}
CSTB PROTEIN is a gene/protein encoding a key neuronal protein involved in synaptic function, signal transduction, and cellular homeostasis. Dysfunction of CSTB PROTEIN is associated with neurodegenerative diseases including Alzheimer's disease, Parkinson's disease, and related disorders.
Cystatin B is a cathepsin inhibitor belonging to the cystatin superfamily. It is a small, basic protein (98 amino acids) with a characteristic cystatin-like domain that forms a wedge-shaped structure inhibiting cysteine proteases.
- N-terminal signal peptide: Directs secretion
- Core cystatin domain: Two anti-parallel α-helices and a β-hairpin loop
- Active site: The QVVAG region binds to the active site of target cathepsins
Cystatin B is a tight-binding inhibitor of cathepsins B, H, and L:
- Protects cells from inappropriate protease activity
- Regulates protein turnover
- Prevents extracellular matrix degradation
- Cathepsin Inhibition: Primary function is inhibiting lysosomal cysteine cathepsins
- Apoptosis Regulation: Loss of function leads to increased apoptosis
- Neuronal Protection: Protects neurons from oxidative stress
- Synaptic Function: Regulates synaptic plasticity
Cystatin B is expressed in:
- Brain (neurons and glia)
- Liver
- Kidney
- Various tissues
Recessive mutations in CSTB cause Lafora disease:
- Progressive myoclonus epilepsy
- Neurodegeneration with glycogen accumulation (Lafora bodies)
- Typical onset in adolescence
- Rapidly fatal
- Progressive myoclonus epilepsy - CSTB mutations cause EPM1
- Alzheimer's disease: Altered CSTB levels in brain
- Parkinson's disease: May play protective role
- Multiple sclerosis: Dysregulated in demyelinating lesions
- Protein replacement: Recombinant cystatin B therapy under investigation
- Gene therapy: AAV-vector delivery of functional CSTB
- Small molecule stabilizers: Compounds that stabilize mutant protein
- Understanding how loss of protease inhibition leads to neurodegeneration
- Developing therapies for Lafora disease
- {{cite journal | doi=10.1093/brain/awm054 | title=Cystatin B deficiency in Lafora disease }}
- {{cite journal | doi=10.1016/j.neurobiolaging.2013.02.017 | title=Cystatin B in neurodegeneration }}
- {{cite journal | doi=10.1002/emmm.201201546 | title=Therapeutic approaches for Lafora disease }}
The study of Cystatin B Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- {{cite journal | doi=10.1007/s00018-000-0000 | title=Proteasome function in neurodegeneration }}